Positions

Professor
Mol & Cell Biology-Sreekumar
Baylor College of Medicine
Houston, TX, US
Director, Metabolomics Shared Resource
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas, United States

Education

Advanced Training from University Of Michigan
Ph.D. from Indian Institute Of Science
M.S. from University Of Pune
BS from University of Mysore

Honors & Awards

Merit Scholarship
Scholarship
Junior and Senior Research Fellowships
Qualified Graduate Aptitude Test in Engineering
In General Science and Engineering with 97.69 percentile. Secured all India 56th rank
Best Poster Award
Post-Doctoral Training Award
2nd Place for Abstract
Awarded a platform presentation as part of the recognition.
Georgia Cancer Coalition Distinguished Scientist
Emerging Scientist Award
ASCO-NCI-EORTC Travel Award
Molecular Cell Biology Departmental Faculty Award for Research Excellence
Challenge Award 2017

Professional Interests

  • Cancer Biology
  • Drug Resistance Mechanisms
  • Metabolism
  • Signal Transduction

Selected Publications

Memberships

Plos One
Scientific Reports
Board Member
Hormones and Cancer (2015-current)
Ad-Hoc Review
Cancer Research
Clinical Cancer Research
Proteomics
Clinical Proteomics
Oncotarget
Molecular Cancer Research
Brazilian Journal of Urology (2013-2014)
Journal of Autism and Developmental Disorders (2013)
PLoS ONE
Metabolomics
Molecular Endocrinology
TARGETS (2010).
Cancer Investigation (2010)
Cancer Epidemiology and Biomarkers
Nanotechnology
Oncogene
Nature Communications
Study Sections
Reviewer for Department of Defense research grants (2011-current, minimum 3 times)
Reviewer for grants submitted to Florida Department of Health (2011-2012, minimum 2 times)
Reviewer for the Cancer Biomarker Study Section, National Cancer Institute (2012, minimum two times)
Reviewer for Clinical Proteomic Technologies for Cancer Initiative (CPTC): Proteome Characterization Centers (U24), National Cancer Institute (2012, once)
Reviewer of NCI Health Disparity Grants, (2012-current, minimum 3 times)
Reviewer of NCI Health Disparity Grants (November 2015)
Reviewer of NCI SBIR grants (2013-2014, minimum two times)
Reviewer of NIH Metabolomics Road Map Initiative Proposals (2013, once)
Reviewer for National Science Foundation grant applications (2014, once)
Reviewer for VA merit grant applications (2014, once)
Reviewer for Komen grant applications (2013-2014, minimum two times)
Reviewer for American Association for Cancer Research (AACR) grant application
Reviewer for Welcome Trust grant applications (2013-2014, minimum two times)
Reviewer of Metabolomics applications for the NIH funded RCMRC cores at Michigan and Mayo Clinic (2012-current, minimum four times).
NIH study section 2015/005 ZRG1 OBT-Z (55), Apr 2015
NIH study section 2016/01 ZRG1 OBT-K (55), Nov 2015
NIH study section 2016/01 ZRG1 OBT-K (50), Nov 2015
DOD Reviewer Exceptional Responders RFA, Nov 2015
NIH study section 2016/05 ZRG1-F09B-B-20, Mar 2016
NIH study section 2016/05 ZRG1OBT-D-55, Apr 2016
NIH study section 2016/08 ZRG1-BST-U-50, Jun 2016
NIGMS study section 2017/01 ZGM1-RCB-3-C3 Nov 2016
DOD Reviewer IDEA grants, Nov 2016.
NIGMS study section 2017/05 ZGM1-BBCB-5-BM Dec 2016
CSR study section 2017/08 ZRG1-BST-H-50 June 2017
NIGMS study section 2017/01 ZGM1-RCB-3-C3 Nov 2017
DOD Reviewer IDEA grants, Nov 2017.
American Association for Cancer Research
Member of American Society for Mass Spectrometry
American Society of Clinical Oncology
Houston Metabolomics Society
Society for Basic Research in Urology Research

Funding

Tumor Metabolomics Core Facility
Unrestricted funding from CPRIT (Edwards)
To establish a cancer metabolomics core facility at Baylor College of Medicine. To support
The role of mitochondrial heterogeneity in pyruvate flux in prostate cancer progression.
- #R21CA205257
Grant funding from NCI
To understand the role of mitochondrial pyruvate transporters in prostate cancer progression.
To develop methods to detect metabolites in biofluids with the longer term goal of applying this to studies in the International Space Station
- #GA-2014-136
Grant funding from CASIS
Delineating racially distinct metabolic pathways in triple negative breast cancer
- #1 U01 CA179674-01A1
Grant funding from NIH
Aim 1: Validate elevated levels of unsaturated fatty acids and lipids in AA TN BCa. Aim 2: Functionally characterize the pathways leading to accumulation of 2-OHG and arachidonic acid in AA TN BCa using in vitro and in vivo models. Aim 3: Measure the serum levels of metabolites in tryptophan, unsaturated fatty acids (including arachidonic acid) and 2-HG pathway in AA TN BCa.
Agilent Mass Spectrometry
Center for Excellence
This grant funds the development of non-invasive metabolic markers in serum/plasma and urine for cancer detection and prognosis.
Genetic and metabolic dissection of the camkk alpha signaling axis in prostate cancer
- #1 R01 CA184208-01A1
Grant funding from NIH
To study the metabolic pathways regulated by camkk alpha signaling axis in prostate cancer. This grant was scored at 4th percentile and is awaiting funding after the council meeting.
SRC-2 driven “metabolic switch” in metastatic prostate cancer- prognostic and therapeutic implications.
- #RP150451
Unrestricted funding from CPRIT
To define the metabolic alterations associated with SRC2 action in Castrate Resistant Prostate
Cancer
Metabolomics Initiative
Grant funding from Diana Helis Henry Medical Research Foundation
To establish a lipidomics facility for Cancer Research
Elucidating the Role of Xenobiotic Metabolism in Bladder Cancer Progression
- #1127430-RSG-15-105-01-CNE
Grant funding from American Cancer Society (ACS)
Define stage specific profiles of key xenobiotic metabolites in bladder cancer, define the regulation and function of AOX1 in bladder cancer and develop a prognostic panel of urinary xenobiotic metabolites.
Baylor College of Medicine Cancer Center
- #2 P30 CA125123-09
Grant funding from NIH/NCI
The purpose of this shared resource is to provide investigators with cost-effective, state-of-the-art instrumentation and specialized expertise for analysis of metabolomics with the goal to identify novel metabolic biomarkers and pathways with application in prevention, diagnosis and treatment of cancer.
Prostate Cancer
Grant funding from Prostate Cancer Foundation
Clinicopathological correlation & molecular signature identification & risk stratification of prostate cancer in African American U.S. Veterans, with & without exposure to battlefield chemicals.
Bladder Cancer and Identification of Altered Metabolism
- #1 R01 CA220297-01
Grant funding from NIH
Racial disparity in bladder cancer and identification of altered metabolism in African American compare to European bladder cancer.
Metabolomic profiling and biologic basis of racial disparity in prostate cancer
- #5 U01 CA167234-03
Grant funding from NCI
Definitively define and compare the PCa metabolome of AA and EA men and uncover the biological mechanism in an ancestry-verified subset of AA and EA prostate cancers. To functionally characterize the race-associated metabolic pathways and evaluate the pathway-associated metabolites in urine specimens from AA and EA men with prostate cancer.
Metabolomic profiling to distinguish racially distinct prognostic markers in prostate cancer
- #W81XWH-12-1-0130
Grant funding from DOD
Metabolomic profiling to distinguish racially distinct prognostic markers in prostate cancer
Goals: specifically address metabolic profiles associated with low/high Gleason grade prostate cancer in AA and EA men and to develop tissue microarray based enzymatic signatures for low or high risk prostate cancer.
To quantify lipids in a randomized fish oil study in prostate cancer patients.
- #W81XWH-12-1-0469
Grant funding from DOD
To use mass spectrometry to quantify lipids in prostate tissues from men enrolled in a randomized fish oil study.
Role: Co-Investigator in the application, Principal Investigator at BCM
Integrative Metabolomics of Prostate Cancer Progression
- #1R01CA133458-01
Grant funding from NIH
Proteomic Profiling of Multiple Myeloma Progression
- #602005
Grant funding from Multiple Myeloma Research Foundation
Integromics with application to prostate cancer progression
- #RCA145444A
Grant funding from NIH/NCI
Role: Co-Principal Investigator
Metabolomic Markers for Early Detection of Prostate Cancer
- #1 R03 CA139489-01
Grant funding from NIH
Development of first-generation multiplex metabolomic biomarker panel in serum for diagnosis and prognosis of breast cancer
- #KG110818
Grant funding from Susan Komen Foundation
The objective of this study is to define and validate the metabolic profiles in tissues and serum from various breast cancer patients. This data was used to develop the subsequent grant applications (including the current one) on breast cancer.
IDH1 and metabolic changes in Dnmt3a KO HSCs
- #DK92883 metabolomics supplement
Grant funding from NIDDK
This is a metabolomic supplement for the associated RO1 to extend the work to study of IDH1 and metabolic changes in Dnmt3a KO HSCs.
Role: Co-Investigator